Analysts forecast that Inogen, Inc (NASDAQ:INGN) will report earnings per share (EPS) of $0.29 for the current quarter, Zacks reports. Two analysts have issued estimates for Inogen’s earnings, with estimates ranging from $0.24 to $0.33. Inogen reported earnings per share of $0.16 in the same quarter last year, which would suggest a positive year-over-year growth rate of 81.3%. The company is scheduled to issue its next earnings results after the market closes on Tuesday, November 7th.
On average, analysts expect that Inogen will report full year earnings of $1.20 per share for the current year, with EPS estimates ranging from $1.17 to $1.23. For the next financial year, analysts forecast that the company will report earnings of $1.30 per share, with EPS estimates ranging from $1.23 to $1.39. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Inogen.
Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, topping the Zacks’ consensus estimate of $0.28 by $0.10. Inogen had a return on equity of 12.45% and a net margin of 10.36%. The company had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. During the same quarter in the previous year, the firm posted $0.25 EPS. The firm’s revenue was up 17.4% compared to the same quarter last year.
A number of equities research analysts recently commented on the stock. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 8th. BidaskClub upgraded shares of Inogen from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 8th. Piper Jaffray Companies restated a “hold” rating and issued a $90.00 price objective on shares of Inogen in a research report on Tuesday, September 12th. Finally, Needham & Company LLC restated a “buy” rating and issued a $108.00 price objective on shares of Inogen in a research report on Friday, September 1st. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Inogen has a consensus rating of “Buy” and a consensus target price of $90.80.
WARNING: “Zacks: Brokerages Anticipate Inogen, Inc (INGN) Will Post Earnings of $0.29 Per Share” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright laws. The correct version of this article can be read at https://www.dispatchtribunal.com/2017/11/12/zacks-brokerages-anticipate-inogen-inc-ingn-will-post-earnings-of-0-29-per-share.html.
In other news, Director Raymond Huggenberger sold 14,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the completion of the transaction, the director now directly owns 7,808 shares of the company’s stock, valued at approximately $715,759.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Matt Scribner sold 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The stock was sold at an average price of $93.88, for a total transaction of $234,700.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 73,667 shares of company stock valued at $7,041,641. 5.31% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. increased its stake in shares of Inogen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 2,150,552 shares of the medical technology company’s stock worth $205,207,000 after purchasing an additional 39,752 shares in the last quarter. Vanguard Group Inc. grew its stake in Inogen by 24.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock worth $144,594,000 after acquiring an additional 301,737 shares during the period. Koch Industries Inc. grew its stake in Inogen by 19,485.8% in the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock worth $650,000 after acquiring an additional 653,747 shares during the period. Dimensional Fund Advisors LP grew its stake in Inogen by 3.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock worth $49,572,000 after acquiring an additional 17,111 shares during the period. Finally, State Street Corp grew its stake in Inogen by 6.8% in the 2nd quarter. State Street Corp now owns 425,662 shares of the medical technology company’s stock worth $40,619,000 after acquiring an additional 27,250 shares during the period.
Shares of Inogen (INGN) traded up 3.54% during mid-day trading on Friday, reaching $98.25. The company’s stock had a trading volume of 126,881 shares. The company’s 50-day moving average is $98.06 and its 200-day moving average is $91.95. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 85.29 and a beta of 0.99. Inogen has a 52 week low of $50.24 and a 52 week high of $105.35.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Get a free copy of the Zacks research report on Inogen (INGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.